A widely available antiviral medication offers new possibilities for long Covid patients seeking relief from debilitating ...

Long COVID remains a major health challenge for millions of people, with symptoms like brain fog lingering for months after ...

Paxlovid use was associated with lower rates of hospitalization and death, particularly among older adults, a new study finds ...

But the report, on the experiences of 13 patients, found that the drug had no benefit for some people and that some who ...

It’s been estimated that about 400 million people worldwide have had long COVID. Some researchers say that number is much higher. But there’s a lack of research on successful treatments for long COVID ...

In this study, the authors estimated that Paxlovid reduced the risk of hospitalization by 39% (95% confidence interval [CI], 36% to 41%), with an absolute risk reduction of 0.9 percentage points. The ...

Paxlovid may offer marginal benefits for low-risk children with COVID-19; however, among high-risk children with COVID-19, Paxlovid is a safe oral option.

In hospitalized COVID-19 patients, azvudine shows lower all-cause mortality and fewer adverse events than Paxlovid, with ...

These findings counter clinical trial results published in June which found that Paxlovid was safe to take but did not lessen ...

Drugmakers plan to raise U.S. prices on at least 250 branded medications including Pfizer PFE.N COVID-19 treatment Paxlovid, Bristol Myers Squibb's BMY.N cancer cell therapies and vaccines ...

The stock has spent the past few years in the shadow of a COVID-19 boost, but it's time investors see the light.

A small study published Monday found that the COVID-19 antiviral treatment Paxlovid may have use as a treatment for long COVID when administered outside of an infection. Administration of Paxlovid ...